Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.58 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.58 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.58 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125513 | 1.00 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913694 | 1.00 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3127433 | 0.87 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913673 | 0.87 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL6387556 | 0.87 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL6232006 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3111100 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913611 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3124700 | 0.84 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3115709 | 0.84 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | claimed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | claimed |
| CN-117045653-A | Diseases and treatments associated with toxic aldehydes | 奥尔德拉医疗公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111135171-B | Diseases and treatments associated with toxic aldehydes | 奥尔德拉医疗公司 | 2023-09-08 | — | — | CN | disclosed |
| US-10543181-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-1480639-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1192125-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000076958-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNB3 2558/4885CACNA1C 3394/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNB3 2558/4885CACNA1C 3394/4885 |
| US-10543181-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.